Atrial fibrillation is not uncommon among patients with ischemic stroke and transient ischemic stroke in China

Xiaomeng Yang¹, Shuya Li², Xingquan Zhao¹,³, Liping Liu⁴,⁵, Yong Jiang²,³, Zixiao Li¹,⁶, Yilong Wang²,⁶* and Yongjun Wang¹,⁵,⁶*

Abstract
Background: Atrial fibrillation (AF) is reported to be a less frequent cause of ischemic stroke in China than in Europe and North America, but it is not clear whether this is due to underestimation. Our aim was to define the true frequency of AF-associated stroke, to determine the yield of 6-day Holter ECG to detect AF in Chinese stroke patients, and to elucidate predictors of newly detected AF.

Methods: Patients with acute ischemic stroke or transient ischemic attack (TIA) were enrolled in a prospective, multicenter cohort study of 6-day Holter monitoring within 7 days after stroke onset at 20 sites in China between 2013 and 2015. Independent predictors of newly-detected AF were determined by multivariate analysis.

Results: Among 1511 patients with ischemic stroke and TIA (mean age 63 years, 33.1% women), 305 (20.2%) had either previously known (196, 13.0%) or AF newly-detected by electrocardiography (53, 3.5%) or by 6-day Holter monitoring (56/1262, 4.4%). A history of heart failure (OR = 4.70, 95%CI, 1.64–13.5), advanced age (OR = 1.06, 95%CI, 1.04–1.09), NIHSS at admission (OR = 1.06, 95%CI, 1.02–1.10), blood high density lipoprotein (HDL) (OR = 1.52, 95%CI, 1.09–2.13), together with blood triglycerides (OR = 0.64, 95%CI, 0.45–0.91) were independently associated with newly-detected AF.

Conclusions: Contrary to previous reports, AF-associated stroke is frequent (20%) in China if systemically sought. Prolonged noninvasive cardiac rhythm monitoring importantly increases AF detection in patients with recent ischemic stroke and TIA in China. Advanced age, history of heart failure, and higher admission NIHSS and higher level of HDL were independent indicators of newly-detected AF.

Trial registration: NCT02156765 (June 5, 2014).

Keywords: Atrial fibrillation, Prolonged ECG monitoring, ischemic stroke, transient ischemic attack, China

Background
The fraction of strokes associated with atrial fibrillation has been reported to be lower in China than in European and North American stroke populations [1–3], but it is not clear whether this is due to its under-detection and hence leading to suboptimal secondary prevention. Recent studies have demonstrated that prolonged (> 24 h) of cardiac rhythm monitoring importantly increases detection of paroxysmal atrial fibrillation in post-stroke patients [4–6], but this has not previously been assessed in Chinese stroke patients, who are on average relatively young. We sought to determine the true frequency of AF-associated stroke and yield of prolonged cardiac rhythm monitoring to detect paroxysmal AF in Chinese patients with recent ischemic stroke and TIA.

Methods
Subjects
From October 2013 to June 2015, we recruited consecutive patients within 7 days of the index event of ischemic stroke or TIA from 20 Chinese hospitals. Clinical TIsas

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
with an acute ischemic lesion visualized on computerized tomography (CT) or magnetic resonance imaging (MRI) were classified as strokes. The exclusionary criteria were 1) age < 18 years; 2) patients who were unable or unwilling to give informed consent; and 3) patients who were found not to have a stroke or TIA (stroke mimics). The study complied with the Declaration of Helsinki, and protocol was approved by the institutional review board (IRB) of Beijing Tiantan Hospital, Capital Medical University. All patients or their legal representatives provided written informed consent.

**Data collection**

Clinical data included demographic information, stroke risk factors, detailed medical history and treatments. Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) [7] assessed by physicians. Patients received routine stroke care according to his/her condition including CT or MRI, 12-channel surface electrocardiography (ECG), transthoracic echocardiography, ultrasound of the cervical arteries, and routine blood analysis including, for example, lipid profile, blood glucose, liver enzymes and creatinine. Previously known AF was diagnosed according to the medical history reported by the patients and the prior medical records of the patients in our study.

**Holter monitoring**

The 6-day Holter monitoring initiated within 7 days after the index event using a commercially available 3-lead monitor device (iHolter, Yocaly Information Science & Technology Co., Ltd. Jinan, Shandong, China). It is an autotriggered device that uses an event detection algorithm to capture asymptomatic paroxysmal events, including paroxysmal AF. The event detection algorithm uses RR interval variability and QRS morphology analysis to detect all possible AF events that are then transmitted to a central core laboratory for manual review and confirmation based on standard diagnostic criteria (absence of p wave activity and irregular RR interval). ECG recordings were analyzed in a central core laboratory by two investigators who were independent of our study team and who were unaware of clinical and neuroimaging results using dedicated analysis software (DoctorClient, Software Version 1.5.0.16). All Holter ECG recordings with suspected AF were subsequently evaluated by another independent observer. Bursts of AF on ECG were reported by the number of beats of each occurrence. The first time and longest duration of bursts of AF for each patient were also recorded. The device defined AF as ≥1 period of >30 s duration of an absolute arrhythmia without detectable P-waves and episodes <30 s require manual review of all possible AF events [8, 9]. Atrial flutter and AF were not discriminated as both arrhythmias carry a similar stroke risk and often coincide [10].

**Statistical analyses**

Continuous data are given as median, range and categorical variables are given as absolute number and percentage. Mann–Whitney U test (continuous variables) and Pearson χ2 tests (categorical variables) were used to compare groups. Significance was assumed when the 2-sided probability value was <0.05. A multivariate analysis was performed using logistic regression, all factors that associated with detected AF in univariate analysis were included (P<0.05). For calculation of 95% confidence interval (CI), binominal distribution was assumed. Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC).

**Results**

**Patient population**

During the study period, 1556 patients with stroke or TIA were admitted to the participating stroke units. Because of artifacts, interruptions for clinical procedures, and early detachment of the monitoring leads by patients, 1511 patients (1441 with ischemic stroke and 70 with TIA) were included (Fig. 1). The mean age of the study cohort was 63 years, and 33.1% were women.

**Detection of Atrial fibrillation**

Among 1511 patients with ischemic stroke and TIA, 305 (20.2%) had previously known (196, 13.0%) or newly detected AF on electrocardiography (53, 3.5%), and 4.4% of patients had unsuspected AF detected by 6-day Holter monitoring (56/1262). The median duration from index event (TIA/stroke) to initiation of monitoring was 4 days (range, 2–5 days). Prolonged Holter monitoring was well tolerated, yielding a median ECG recording duration of 5 days (range, 5–6 days). Cumulative overall detection rates of 56 unsuspected AF detected by 6-day Holter monitoring were shown in Fig. 2. Patients with TIA/stroke frequently revealed other significant dysrhythmias, including 1) premature atrial complexes (1099, 72.7%); 2) premature ventricular complexes (1123, 74.3%); 3) atrial tachycardia (728, 48.2%); 4) ventricular tachycardia (142, 9.4%).

**Patient characteristics**

Cohort characteristics, comparing patients with and without AF, are presented in Table 1. Older patients (median 72 vs. median 61; P<0.001) and patients who are not current smokers (81.0% vs. 63.8%; P<0.001) were more likely to have AF. Patients with AF were presented more frequently with previous ischemic stroke (27.2% vs. 21.1%; P=0.02), coronary heart disease (17.7% vs. 8.3%; P<0.001), heart failure (9.5% vs. 1.0%,
Admitted between October 2013 and June 2015 with Ischemic stroke or TIA in 20 stroke centers (n=1556)

6-days Holter ECG

\[\text{Informed consent withdrawn or otherwise invalid (n=20); Duration between onset to Holter monitoring > 7 days (n=7); Insufficient quality of report for further statistical analysis (n=18)}\]

Ischemic stroke (n=1441) and TIA (n=70) in the final analysis (n=1511)

Previously unknown AF (n=1315)

Previously known AF (n=196)

Detected AF by ECG at admission (n=53)

Patients without AF after ECG at admission (n=1262)

AF detected by 6-day Holter (n=56)

Patients without AF (n=1206)

**Fig. 1** Flow chart of the study

**Fig. 2** Cumulative overall detection rates of 56 unsuspected AF detected by 6-day Holter monitoring
and higher NIHSS score at admission (median 4 vs. 3; P < 0.001). Considering laboratory tests, patients with AF had, on average, lower levels of triglycerides (median 1.05 vs. 1.40; P < 0.001) and LDL (median 2.57 vs. median 2.74; P = 0.001) and cholesterol (median 4.35 vs. median 4.55; P = 0.002) and had higher levels of HDL (median 1.20 vs. 1.12; P < 0.001).

In multivariable analysis (Table 2), a history of coronary heart disease (OR = 1.65, 95% CI, 1.08–2.50) and heart failure (OR = 7.11, 95% CI, 3.22–15.72), advanced age (OR = 1.06, 95% CI, 1.05–1.08), admission NIHSS (OR = 1.06, 95% CI, 1.04–1.09), HDL (OR = 1.41, 95% CI, 1.02–1.94) together with current smoker (OR = 0.68, 95% CI, 0.48–0.97) and blood triglycerides (OR = 0.78, 95% CI, 0.65–0.94) were independently associated with AF in patients with ischemic stroke and TIA.

We also compared the characteristics of patients with previously known/ newly-detected AF and without AF (Table 3). Older patients (median 72 vs. median 61; P < 0.001) and patients who are not current smokers (77.1% vs. 63.8%; P = 0.006) were more likely to have newly-detected AF. Patients with newly-detected AF were presented more frequently with previous TIA (6.4% vs. 1.0%; P < 0.001), coronary heart disease (17.4% vs. 8.3%; P = 0.001), heart failure (6.4% vs. 1.0%; P < 0.001), higher NIHSS score at admission (median 4 vs. 3; P < 0.001) and less frequently with previous hyperlipidemia (8.3% vs. 15.9%; P = 0.03). Considering laboratory tests, patients with newly-detected AF had, on average, lower levels of triglycerides (median 1.03 vs. 1.40; P < 0.001) and cholesterol (median 4.38 vs. median 4.55; P = 0.05) and had higher levels of HDL (median 1.22 vs. 1.12; P = 0.002).

In multivariable analysis (Table 4), a history of heart failure (OR = 4.70, 95% CI, 3.22–15.72), advanced age

| Table 1 | Patient features associated with AF |
|-----------------|-----------------|-------------------------------|---------------------------------|-----------------|
| Variables       | All patients (n = 1511) | Without AF (n = 1206) | With AF (n = 305) | P Value |
| Age, yr. (median[IQR]) | 63(55–73) | 61(53–71) | 72(64–78) | < 0.001 |
| Women, n(%) | 500(33.1) | 385 (31.9) | 115(37.7) | 0.06 |
| BMI,Kg/m² (median[IQR]) | 24.2(22.0–26.4) | 24.2(22.0–26.4) | 24.2(21.5–26.3) | 0.08 |
| Current smoker,n(%) | 494(32.7) | 436(36.2) | 58(19.0) | < 0.001 |
| Medical history, (%) | | | | |
| Hypertension | 949(62.8) | 750 (62.2) | 199 (65.2) | 0.32 |
| Diabetes | 326(21.6) | 254 (21.1) | 72 (23.6) | 0.33 |
| Hyperlipidemia | 227(15.0) | 192 (15.9) | 35(11.5) | 0.052 |
| Ischemic stroke | 337(22.3) | 254 (21.1) | 83 (27.2) | 0.02 |
| TIA | 43(2.8) | 36 (3.0) | 7(2.3) | 0.52 |
| MI | 45(3.0) | 33 (2.7) | 12 (3.9) | 0.27 |
| Coronary heart disease | 154(10.2) | 100(8.3) | 54(17.7) | < 0.001 |
| Peripheral arterial disease | 32(2.1) | 23(1.9) | 9(3.0) | 0.26 |
| Heart failure | 41(2.7) | 12 (1.0) | 29(9.5) | < 0.001 |
| Blood analysis(mmol/L) | | | | |
| Triglycerides | 1.33(0.90–1.91) | 1.40(0.96–2.00) | 1.05(0.78–1.56) | < 0.001 |
| LDL | 2.70(2.20–3.31) | 2.74(2.23–3.35) | 2.57(2.05–3.22) | 0.001 |
| HDL | 1.12(0.96–1.34) | 1.12(0.96–1.34) | 1.20(1.00–1.41) | 0.002 |
| Cholesterol | 4.52 (3.90–5.24) | 4.55(3.93–5.29) | 4.35(3.76–5.06) | 0.002 |
| Fasting blood-glucose | 5.49(4.92–6.81) | 5.47(4.92–6.81) | 5.60(4.94–6.83) | 0.42 |

| Table 2 | Multivariate analysis of clinical features associated with AF |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Variables       | OR   | 95% CI | P value | 
| Age | 1.06 | 1.04–1.08 | < 0.001 | 
| Previous coronary heart disease | 2.00 | 1.31–3.05 | 0.001 | 
| Previous heart failure | 7.36 | 3.38–16.05 | < 0.001 | 
| NIHSS at admission | 1.05 | 1.03–1.08 | < 0.001 | 
| Current smoker | 0.65 | 0.45–0.93 | 0.02 | 
| Triglycerides | 0.76 | 0.63–0.91 | 0.004 | 

IQR indicates interquartile range, TIA transient ischemic attack, MI myocardial infarction, NIHSS the National Institutes of Health Stroke Scale, LDL low density lipoprotein, HDL high density lipoprotein.
(OR = 1.06, 95%CI, 1.04–1.09), admission NIHSS (OR = 1.06, 95%CI, 1.02–1.10), HDL (OR = 1.52, 95%CI, 1.09–2.13) together with blood triglycerides (OR = 0.64, 95%CI, 0.45–0.91) were independently associated with newly-detected AF.

### Discussion

Contrary to previous reports, AF-associated brain ischemia is frequent (20.2%) in China. Identification of AF after ischemic stroke or TIA is crucial to optimize appropriate anticoagulation. This is the first study to demonstrate the yield of prolonged cardiac rhythm monitoring after ischemic stroke and TIA in Chinese patients with recent brain ischemia. This prospective multicenter study provides solid evidence that AF is considerably more common in patients with ischemic stroke and TIA than what has been reported in most previous population-based studies in China [2, 3, 11]. The underlying reasons are likely the increased duration of cardiac rhythm monitoring in comparison to prior studies and AF detection based upon a standardized automated arrhythmia detection algorithm and continuous review of monitoring data.

However, when compared with the studies in western countries [12, 13], the overall detection rate of AF among stroke and TIA is still lower. In our study the detection rate of any new AF among patients without previously known AF were respectively 5.2% and 6.9% in the first 24 h and during the whole monitoring period while the rate were 6.2% and 14.1% in a recent review [14]. The discrepancy might be because the patients in our study are, on average younger (mean age, 63.0 years)

---

**Table 3** Patient characteristics with previously known, newly detected AF or without AF

| Variables                  | Without AF (n = 1206) | Previously known AF (n = 196) | Newly detected AF (n = 109) | P Value* | P Value† |
|----------------------------|-----------------------|-------------------------------|-----------------------------|----------|----------|
| Age, yr. (median[IQR])     | 61(53–71)             | 72(64–78)                     | 72(64–78)                   | < 0.001  | < 0.001  |
| Women, n (%)               | 385(31.9)             | 75(38.3)                      | 40(36.7)                    | 0.08     | 0.31     |
| BMI, Kg/m² (median[IQR])   | 24.2(22.0–26.4)       | 24.2(21.3–26.4)               | 23.8(21.9–25.6)             | 0.27     | 0.11     |
| Current smoker, n (%)      | 436(36.2)             | 33(16.8)                      | 25(22.9)                    | < 0.001  | 0.006    |
| Medical history, (%)       |                       |                               |                             |          |          |
| Hypertension               | 750(62.2)             | 136(69.4)                     | 63(57.8)                    | 0.053    | 0.37     |
| Diabetes                   | 254(21.1)             | 46(23.5)                      | 26(23.9)                    | 0.45     | 0.50     |
| Hyperlipidemia             | 192(15.9)             | 26(13.3)                      | 9(8.3)                      | 0.34     | 0.03     |
| Ischemic stroke            | 254(21.1)             | 67(34.2)                      | 16(14.7)                    | < 0.001  | 0.11     |
| TIA                        | 12(1.0)               | 6(3.1)                        | 7(6.4)                      | 0.95     | < 0.001  |
| MI                         | 33(2.7)               | 7(3.6)                        | 5(4.6)                      | 0.52     | 0.42     |
| Coronary heart disease     | 100(8.3)              | 35(17.9)                      | 19(17.4)                    | < 0.001  | 0.001    |
| Peripheral arterial disease| 23(1.9)               | 8(4.1)                        | 1(0.9)                      | 0.10     | 0.71     |
| Heart failure              | 12(1.0)               | 22(11.2)                      | 7(6.4)                      | < 0.001  | 0.001    |
| Blood analysis (mmol/L)    |                       |                               |                             |          |          |
| Triglycerides              | 1.40(0.96–2.00)       | 1.05(0.75–1.60)               | 1.03(0.81–1.48)             | < 0.001  | < 0.001  |
| LDL                        | 2.74(2.23–3.35)       | 2.49(2.03–3.25)               | 2.65(2.13–3.17)             | 0.003    | 0.07     |
| HDL                        | 1.12(0.96–1.34)       | 1.19(0.99–1.38)               | 1.22(1.02–1.45)             | 0.06     | 0.002    |
| Cholesterol                | 4.55(3.93–5.29)       | 4.28(3.73–5.14)               | 4.38(3.77–4.94)             | 0.01     | 0.05     |
| Fasting blood-glucose      | 5.47(4.92–6.81)       | 5.63(4.90–7.10)               | 5.50(4.87–6.51)             | 0.18     | 0.67     |

Clinical features (median[IQR])

| NIHSS at admission         | 3(1–6)                | 4(2–9)                         | 4(2–10)                     | < 0.001  | < 0.001  |

---

**Table 4** Multivariate analysis of clinical features independently predictive of newly detected AF

| Variables                  | OR         | 95% CI     | P value |
|----------------------------|------------|------------|---------|
| Age                        | 1.06       | 1.04–1.09  | < 0.001 |
| Previous heart failure     | 4.70       | 1.64–13.5  | 0.004   |
| NIHSS at admission         | 1.06       | 1.02–1.10  | 0.003   |
| Triglycerides              | 0.64       | 0.45–0.91  | 0.01    |
| HDL                        | 1.52       | 1.09–2.13  | 0.02    |

NIHSS the National Institutes of Health Stroke Scale, LDL low density lipoprotein, HDL high density lipoprotein

---

*P values for comparation between patients with previously known AF and those without AF
†P values for comparation between patients with newly-detected AF and those without AF
than in studies reporting higher frequencies AF in which the mean ages was 68.4 years. When compared with studies with the similar monitoring duration, Stahenberg et al. [12] and Jabaudon et al. [15] have reported higher detection rates of new AF using 7-day continuous Holter monitoring and 7-day event-loop recording (ELR) device (12.5% and 14.8% respectively). The early time point of monitoring after symptom onset (9.5 h) and relatively older patients in their studies may be the explanation for the difference.

In our study, we found that patients with history of previous coronary heart disease have a higher likelihood of AF which is consistent with previous study [16]. We suppose that the explanation might be that coronary heart disease shares similar risk factors such as aging and systemic vascular risk factors with AF which may cause an abnormal atrial tissue substrate or atrial cardio-pathy, that can result in AF.

We also found that current smoker was less likely to have AF in our study which is in accordance with previous study [13]. However, this is inconsistent with recent study investigating the association between smoking and AF in community population which have shown smoking was associated with the incidence of AF [17]. We speculate that the inconsistency may lie in the different population. As we known smoking is an important and potent risk factor for atherosclerosis which may be the main reason for stroke in patients without AF, accordingly the percentage of current smoker is higher in stroke patients without AF. Prospective studies about the association between smoking and AF in stroke patients are needed in the future.

Several factors were significantly associated with an increased risk of new AF detection, namely older age, NIHSS at admission and previous heart failure and HDL. Our results are in line with previous studies in which advanced age was shown to be associated with a higher incidence of AF and paroxysmal atrial fibrillation (pAF) after stroke [16, 18, 19]. This argues for a structural abnormality of the atria with age which may lead to electrical instability thus causing pAF. As cardioembolic strokes are frequently larger and associated with an adverse outcome than those due to other sources [20], we also found that higher NIHSS score at admission is an independent predictor of detection of AF.

In addition, we found that patients with history of heart failure to have a higher likelihood of newly detected AF which is in accordance with previous studies [16, 21]. Previous study also showed preexisting heart disease is the major cause of AF that is first diagnosed after stroke [21], so more intensified screening for AF in these patients may be essential and meaningful.

We also observed independent association between blood triglycerides/HDL and detected AF. The association between blood lipids and AF risk has been reported by several previous publications which have offered inconsistent results [22]. Lack of adjustment for important confounders and inclusion of lipid-lowering medication users may affect the finding in our study which should be explained in caution.

There are limitations to our study: firstly, patients enrolled in our study had, on average, relatively mild strokes which enabled them to complete the study protocol. As cardioembolism is likely to cause large, severe strokes, the detection rate of AF may be underestimated in our study. Secondly, because our analysis focused on the usefulness of Holter monitoring on detection of AF, detailed diagnostic workup such as transesophageal echocardiography or additional biomarkers were only completed in some patients. This limited the predictive model regarding clinical indicators that be associated with decreased risk of AF. Thirdly, some of the brief occurrences of AF may represent stroke-induced arrhythmias rather than being the cause of the stroke. However, whether pAF occurred before or after the stroke will always be difficult to clarify because prestroke monitoring is not available.

**Conclusion**

In conclusion, we found that AF is more common among patients with ischemic stroke and TIA in China than those previously reported. For the first time in a Chinese population, we have demonstrated that AF can be detected in an important fraction of patients with ischemic stroke and TIA via prolonged monitoring evaluation. Clinicians should plan the best available combination of post-stroke atrial fibrillation screening methods to increase yield of AF detection in the shortest possible time after stroke or TIA in order to optimize secondary antithrombotic management.

**Abbreviations**

AF: Atrial fibrillation; CI: Confidence interval; CT: Computerized tomography; ELR: Event-loop recording; HDL: High density lipoprotein; IQR: Interquartile range; LDL: low density lipoprotein; MI: Myocardial infarction; MRI: Magnetic resonance imaging; NIHSS: National Institutes of Health Stroke Scale; OR: Odds-Ratio; pAF: Paroxysmal Atrial fibrillation; TIA: Transient ischemic attack.

**Acknowledgments**

We thank all participating hospitals, their physicians and nurses.

**Funding**

This study was funded by grants from the Ministry of Science and Technology of the People’s Republic of China (2011BA08B02, 2012ZX09303, and 2013BA09B03), Beijing Institute for Brain Disorders (BIBD-PXM2013_014226_07_000084). This study was sponsored and funded by Bayer HealthCare Pharmaceuticals. Bayer HealthCare Pharmaceuticals took no part in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.
This study was sponsored and funded by Bayer HealthCare Pharmaceuticals.

Competing interests
Not applicable

The study complied with the Declaration of Helsinki, and protocol was Ethics approval and consent to participate approved the final manuscript.

Consent for publication
Not applicable

Competing interests
This study was sponsored and funded by Bayer HealthCare Pharmaceuticals.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors’ contributions
Dr. LPL, Dr. XQZ, Dr. WLW, Dr. YJW, contributed to the design of the study; Dr. XMY, Dr. SYL and Dr. ZXJ contribute to acquisition of data and interpretation of data. Dr. YJ contributes to data cleansing and analysis. Dr. XMY contributes to Literature search and draft writing. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study complied with the Declaration of Helsinki, and protocol was approved by the IRB of Beijing Tiantan Hospital, Capital Medical University. All patients or their legal representatives provided written informed consent.

References
1. Wang C, Yang Z, Wang C, Wang Y, Zhao X, Liu L, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the china national stroke registry. J Stroke Cerebrovasc Dis. 2014;23:1157–63.
2. Gao Q, Fu X, Wei JW, Chen X, Huang Y, Wang J, et al. Use of oral anticoagulation among stroke patients with atrial fibrillation in china: the chinaqina (quality evaluation of stroke care and treatment) registry study. Int J Stroke. 2013;8:150–4.
3. Lin S, Wu B, Hao ZL, Kong FY, Tao WD, Wang DR, et al. Characteristics, treatment and outcome of ischemic stroke with atrial fibrillation in a chinese hospital-based stroke study. Cerebrovasc Dis. 2011;31:419–26.
4. Wachter R, Groschel K, Gelbrich G, Hermann GF, Kermer P, Liman J, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (find-af-randomised): an open-label randomised controlled trial. Lancet Neurol. 2017;16:282–90.
5. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478–86.
6. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467–77.
7. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–70.
8. Kirchhof P, Aurichio A, Bar J, Crijns H, Camm J, Diener HC, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the german atrial fibrillation competence network and the european heart rhythm association. Europace. 2007;9:1006–23.
9. Fuster V, Ryden LE, Cannon DS, Crijns HJ, Curtis AB, Ebelligen KA, et al. 2011 acc/aahf focused updates incorporated into the acc/aahf/esc 2006 guidelines for the management of patients with atrial fibrillation: a report of the american college of cardiology foundation/american heart association task force on practice guidelines developed in partnership with the european society of cardiology and in collaboration with the european heart rhythm association and the heart rhythm society. J Am Coll Cardiol. 2011;57:e101–98.
10. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: an update of the 2010 esc guidelines for the management of atrial fibrillation. Developed with the special contribution of the european heart rhythm association. Eur Heart J. 2012;33:2719–47.
11. Li SY, Zhao XQ, Wang CX, Liu LP, Liu GF, Wang YL, et al. One-year clinical prediction in chinese ischemic stroke patients using the cha2ds2-vasc and cha2ds2-vasc scores: the china national stroke registry. CNS Neurosci Ther. 2012;18:988–93.
12. Stahenberg R, Weber-Kruger M, Seegers J, Edelmann F, Lahno R, Haase B, et al. Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke. 2010;41:2884–8.
13. Friberg L, Rosenqvist M, Lindgren A, Terent A, Norving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke. 2014;45:2590–6.
14. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45:520–6.
15. Jabbour D, Szatjel J, Sievert K, Landis T, Szatjel R. Usefulness of ambulatory 7-day ecg monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke. 2004;35:1467–71.
16. Wohlfahrt J, Stahenberg R, Weber-Kruger M, Groschel S, Water K, Edelmann F, et al. Clinical predictors to identify paroxysmal atrial fibrillation after ischaemic stroke. Eur J Neurol. 2014;21:21–7.
17. Chamberlain AM, Aganval SK, Folsom AR, Duval S, Soliman EZ, Ambrose M, et al. Smoking and incidence of atrial fibrillation: results from the atherosclerosis risk in communities (arc) study. Heart Rhythm. 2011;8:1160–6.
18. Doliwa Sobociński P, Anggardh R, Ekkermann V, von Arbin M, Wallen H, Rosenqvist M. Improved screening for silent atrial fibrillation after ischaemic stroke. Europace. 2012;14:1112–6.
19. Alhadramy O, Jeerakathil TJ, Majumdar SR, Najjar E, Choy J, Saqq M. Prevalence and predictors of paroxysmal atrial fibrillation on holter monitor in patients with stroke or transient ischemic attack. Stroke. 2010;41:2596–600.
20. Grau AJ, Weimar C, Buggle F, Heinrich A, Goetler M, Neumaier S, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the german stroke data bank. Stroke. 2001;32:2559–66.
21. Rizos T, Horstmann S, Dittgen F, Tager T, Jenetzy E, Heuschmann P, et al. Preeexisting heart disease underlies newly diagnosed atrial fibrillation after acute ischemic stroke. Stroke. 2016;47:336–41.
22. Alonso A, Yin X, Roetker NS, Magnani JW, Kronmal RA, Ellinor PT, et al. Blood lipids and the incidence of atrial fibrillation: the multi-ethnic study of atherosclerosis and the framingham heart study. J Am Heart Assoc. 2014;3:e001211.